Medicamen Biotech balance sheet

As of Mar 2026

Total assets: ₹372cr+25.3% on Mar 2025
Shareholders' equity: ₹276cr+29.5% on Mar 2025
Total debt: ₹47.8cr+43.7% on Mar 2025
Cash and investments: ₹31.3cr+731.6% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	84.1	86.1	91.0	91.8
	0.6	0.7	0.9	0.9
	5.0	1.2	1.2	1.1
	5.0	1.2	1.2	1.1
	3.2	2.8	2.5	1.9
	55.5	41.4	39.4	19.5
	148	132	135	115
	70.1	62.1	59.4	45.1
	81.8	68.9	55.3	65.3
	31.3	3.8	14.8	20.8
	2.7	0.0	0.0	0.0
	37.9	3.1	4.5	6.9
	—	26.7	—	—
	154	102	74.5	93.0
	—	—	25.7	25.3
	224	165	160	163
	372	297	295	279
Equity
	13.6	12.7	12.7	12.7
	262	200	188	181
	276	213	200	193
	276	213	200	193
Liabilities
	6.2	3.7	1.3	0.9
	6.2	3.7	1.3	0.9
	2.4	2.2	1.8	1.7
	—	−0.0	—	—
	8.5	5.9	3.0	2.5
	41.6	29.5	29.6	23.3
	40.0	42.6	45.4	47.6
	2.5	1.9	11.1	—
	84.1	74.0	86.0	70.9
	1.2	0.8	0.9	0.7
	2.6	3.3	4.1	3.7
	—	—	—	7.3
	87.9	78.2	91.0	82.6
	96.4	84.1	94.0	85.1
	372	297	295	279
Trade payables — MSME split
	1.0	0.0	—	—
	39.0	42.6	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDICAMEQ₹254.25

Medicamen Biotech Limited

· Pharma & Health

₹ CrorePeersMEDICO AAREYDRUGS NECLIFE HALEOSLABS ALBERTDAVD NATCAPSUQ VALIANTLAB BALPHARMAMcap ₹345 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	91.8	91.0	86.1	84.1	84.1
+ Other Intangibles	0.9	0.9	0.7	0.6	0.6
+ Long-term Loans	1.1	1.2	1.2	5.0	5.0
Non-current Financial Assets	1.1	1.2	1.2	5.0	5.0
+ Deferred Tax Assets	1.9	2.5	2.8	3.2	3.2
+ Other Non-current Assets	19.5	39.4	41.4	55.5	55.5
Total Non-current Assets	115.2	134.9	132.3	148.3	148.3
Current Assets
+ Inventories	45.1	59.4	62.1	70.1	70.1
+ Trade Receivables	65.3	55.3	68.9	81.8	81.8
+ Cash & Cash Equivalents	20.8	14.8	3.8	31.3	31.3
+ Other Bank Balances	0.0	0.0	0.0	2.7	2.7
+ Short-term Loans	6.9	4.5	3.1	37.9	37.9
+ Other Current Financial Assets	—	—	26.7	—	—
Current Financial Assets	93.0	74.5	102.4	153.7	153.7
+ Other Current Assets	25.3	25.7	—	—	—
Total Current Assets	163.4	159.6	164.5	223.7	223.7
Total Assets	278.5	294.5	296.9	372.0	372.0
Equity
+ Equity Share Capital	12.7	12.7	12.7	13.6	13.6
+ Other Equity / Reserves	180.8	187.8	200.1	262.0	262.0
Equity — Owners of Parent	193.4	200.5	212.8	275.6	275.6
Total Equity	193.4	200.5	212.8	275.6	275.6
Liabilities
+ Borrowings — Non-current	0.9	1.3	3.7	6.2	6.2
Non-current Financial Liabilities	0.9	1.3	3.7	6.2	6.2
+ Provisions — Non-current	1.7	1.8	2.2	2.4	2.4
+ Deferred Tax Liabilities	—	—	-0.0	—	—
Non-current Liabilities	2.5	3.0	5.9	8.5	8.5
+ Borrowings — Current	23.3	29.6	29.5	41.6	41.6
+ Trade Payables	47.6	45.4	42.6	40.0	40.0
+ Other Current Financial Liab	—	11.1	1.9	2.5	2.5
Current Financial Liabilities	70.9	86.0	74.0	84.1	84.1
+ Provisions — Current	0.7	0.9	0.8	1.2	1.2
+ Current Tax Liabilities	3.7	4.1	3.3	2.6	2.6
+ Other Current Liabilities	7.3	—	—	—	—
Current Liabilities	82.6	91.0	78.2	87.9	87.9
Total Liabilities	85.1	94.0	84.1	96.4	96.4
Total Equity & Liabilities	278.5	294.5	296.9	372.0	372.0
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	0.0	1.0	1.0
+ Dues to Other Creditors — Current	—	—	42.6	39.0	39.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.